Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 + HLX04 vs Sorafenib in Advanced HCC
NCT04465734Phase 3Withdrawn
- Sponsor
- Henlius
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in hepatocellular carcinoma (HCC), sponsored by Henlius. Planned start Nov 2022; status: withdrawn.
02
Drugs
serplulimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04465734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04465734.